Thymosin Alpha-1 + LL-37 + BPC-157: The Immune Restoration Stack
Thymosin Alpha-1
Thymic peptide enhancing T-cell maturation and adaptive immune function
LL-37
Human cathelicidin antimicrobial peptide for innate immune defence
BPC-157
Cytoprotective peptide supporting tissue repair and reducing inflammation
This three-peptide stack targets immune restoration from multiple angles: adaptive immunity (Thymosin Alpha-1), innate antimicrobial defence (LL-37), and tissue repair with anti-inflammatory support (BPC-157).
Thymosin Alpha-1 (Tα1) is the most clinically validated peptide in this stack, with approval in over 35 countries for hepatitis B and as an immune adjuvant. LL-37 is the only human cathelicidin — a broad-spectrum antimicrobial peptide that also modulates immune signalling. BPC-157 provides cytoprotective and anti-inflammatory support.
**Critical Disclaimer:** This combination has not been studied as a stack. Thymosin Alpha-1 is approved in some countries but not in the UK/EU for this indication. LL-37 and BPC-157 are research compounds. This content is educational only.
Synergistic Mechanism
Triple-Pathway Immune Synergy
Thymosin Alpha-1: Adaptive Immunity
- Promotes T-cell maturation and differentiation in the thymus
- Enhances dendritic cell function (antigen presentation)
- Increases NK cell activity
- Modulates cytokine production (balances Th1/Th2 response)
- Approved for hepatitis B in 35+ countries
LL-37: Innate Immunity
- Directly kills bacteria, fungi, and enveloped viruses via membrane disruption
- Modulates TLR signalling (bridges innate and adaptive immunity)
- Promotes wound healing and angiogenesis at infection sites
- Recruits immune cells to sites of infection
- Neutralises bacterial endotoxins (LPS)
BPC-157: Tissue Support
- Reduces inflammatory cytokines (TNF-α, IL-6)
- Promotes tissue repair in gut and other mucosal surfaces
- Supports angiogenesis for immune cell delivery
- Cytoprotective against various tissue insults
- May support gut-associated lymphoid tissue (GALT)
The Combined Logic
1. Tα1 strengthens the adaptive immune system (T-cells, NK cells)
2. LL-37 provides frontline antimicrobial defence
3. BPC-157 repairs damaged tissue and reduces excessive inflammation
4. Together: enhanced immune surveillance + antimicrobial defence + tissue recovery
Research Evidence
Research Evidence
Thymosin Alpha-1
- Approved medication in 35+ countries
- Phase II/III trials for hepatitis B, hepatitis C, and cancer immunotherapy adjunct
- Demonstrated T-cell enhancement and improved vaccine response in elderly populations
- COVID-19 studies showed potential benefit in critically ill patients
LL-37
- The only human cathelicidin — well-characterised antimicrobial spectrum
- Demonstrated efficacy against drug-resistant bacteria in vitro
- Wound healing studies show improved closure and reduced infection
- Immunomodulatory effects validated in multiple preclinical models
BPC-157
- Extensive preclinical data for anti-inflammatory and tissue repair effects
- Demonstrated cytoprotection across GI tract, tendons, muscles, and nervous system
- Limited human safety/efficacy data
Combination Evidence
No published studies examine this specific three-peptide combination.
Theoretical Protocol
Theoretical Protocol
Thymosin Alpha-1:
- Dose: 1.6 mg subcutaneous
- Frequency: 2x per week (e.g., Monday and Thursday)
- This mirrors approved clinical dosing
LL-37:
- Dose: 50-100 mcg subcutaneous
- Frequency: Daily or every other day
- Duration limited (theoretical antimicrobial resistance concern)
BPC-157:
- Dose: 200-500 mcg subcutaneous
- Frequency: 1-2x daily
- Can be taken continuously
**Cycle:** 4-8 weeks, with reassessment
⚠️ Theoretical extrapolations only. No approved combination protocols exist.
Timing & Scheduling
Timing Considerations
- Thymosin Alpha-1: Morning administration, any day
- LL-37: Can be administered any time; consider proximity to areas of concern
- BPC-157: Flexible timing; twice daily split dosing common
- No known timing interactions between the three peptides
- All are subcutaneous injections; can be administered at different sites simultaneously
Expected Outcomes
Expected Research Outcomes
**Thymosin Alpha-1:** Enhanced T-cell counts and function, improved vaccine response, potential viral load reduction
**LL-37:** Antimicrobial support, potential reduction in recurrent infections
**BPC-157:** Reduced tissue inflammation, gut barrier support, general cytoprotection
Timeline:
- Weeks 1-2: Immune marker changes may begin (T-cell subsets)
- Weeks 3-4: Functional immune improvement may be observable
- Weeks 4-8: Full protocol effect period
Safety Considerations
Safety Considerations
- Thymosin Alpha-1: Well-characterised safety from clinical use; injection site reactions, rare flu-like symptoms
- LL-37: Theoretical concern about antimicrobial resistance with chronic use; limit duration
- BPC-157: Limited human safety data; generally well-tolerated in anecdotal reports
- Combined immune stimulation should be monitored — over-activation could theoretically worsen autoimmune conditions
- Contraindicated in active autoimmune disease without specialist supervision
- Blood work: CBC with differential, CRP, immunoglobulin levels
Frequently Asked Questions
Conclusion
The Thymosin Alpha-1 + LL-37 + BPC-157 stack represents a multi-pathway approach to immune restoration research, targeting adaptive immunity, innate defence, and tissue support simultaneously. Thymosin Alpha-1 is the most clinically validated component. This combination is theoretical and unstudied as a stack.